NCT02058706View on ClinicalTrials.gov

LHRH Analogue Therapy With Enzalutamide or Bicalutamide in Treating Patients With Hormone Sensitive Prostate Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

71

Participants

Timeline

Start Date

May 31, 2014

Primary Completion Date

March 1, 2021

Study Completion Date

March 1, 2021

Conditions
Adenocarcinoma of the ProstateRecurrent Prostate CancerStage IV Prostate Cancer
Interventions
DRUG

enzalutamide

Given PO

DRUG

bicalutamide

Given PO

PROCEDURE

orchiectomy

Undergo orchiectomy or receive LHRH analogue therapy

DRUG

leuprolide acetate

Undergo orchiectomy or receive LHRH analogue therapy

DRUG

goserelin acetate

Undergo orchiectomy or receive LHRH analogue therapy

OTHER

laboratory biomarker analysis

Correlative studies

Trial Locations (4)

35294

University of Alabama at Birmingham, Birmingham

43210

Ohio State University Medical Center, Columbus

48201

Barbara Ann Karmanos Cancer Institute, Detroit

48202

Henry Ford Hospital, Detroit

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

Barbara Ann Karmanos Cancer Institute

OTHER

NCT02058706 - LHRH Analogue Therapy With Enzalutamide or Bicalutamide in Treating Patients With Hormone Sensitive Prostate Cancer | Biotech Hunter | Biotech Hunter